According to Gene Expression Profiling Interactive Analysis (GEPIA) analysis based on TCGA data, expressions of GPX4 were universally upregulated across various cancer types, and high GPX4 was associated with adverse clinical outcomes in patients with different cancers, including head and neck cancer (Fig. S4A–C). Here, GPX4 is linked to cancer.